Pseudoprogression after glioma therapy: a comprehensive review (Q38094809)

28 August 2017

Pseudoprogression after glioma therapy: a comprehensive review (English)

1 reference

28 August 2017

Tim J Kruser

1

1 reference

ORCID Public Data File 2021

author name string

Minesh P Mehta

series ordinal

2

1 reference

PubMed ID

23545054

28 August 2017

H Ian Robins

series ordinal

3

1 reference

28 August 2017

1 April 2013

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

28 August 2017

1 reference

28 August 2017

13

1 reference

28 August 2017

4

1 reference

28 August 2017

389-403

1 reference

Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial

28 August 2017

1 reference

Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Stud

21 January 2018

1 reference

Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery

21 January 2018

1 reference

Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protoco

21 January 2018

1 reference

Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme

21 January 2018

1 reference

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

Therapeutic options for recurrent high-grade glioma in adult patients: recent advances

21 January 2018

1 reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis?

21 January 2018

1 reference

FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme

21 January 2018

1 reference

Therapeutic advances in malignant glioma: current status and future prospects

21 January 2018

1 reference

Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system

21 January 2018

1 reference

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

21 January 2018

1 reference

Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.

21 January 2018

1 reference

The concepts, diagnosis and management of early imaging changes after therapy for glioblastomas

21 January 2018

1 reference

Efficacy of temozolomide as adjuvant chemotherapy after postsurgical radiotherapy alone for glioblastomas

21 January 2018

1 reference

Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients

21 January 2018

1 reference

Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression.

21 January 2018

1 reference

Evaluation of malignant glioma patients during the postirradiation period

21 January 2018

1 reference

Transient early computed tomographic changes mimicking tumor progression after brain tumor irradiation.

21 January 2018

1 reference

Reversible neurotoxicity following hyperfractionated radiation therapy of brain stem glioma.

21 January 2018

1 reference

Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression

21 January 2018

1 reference

Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma

21 January 2018

1 reference

Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms

21 January 2018

1 reference

Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide

21 January 2018

1 reference

Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology

21 January 2018

1 reference

Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations

21 January 2018

1 reference

Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma

21 January 2018

1 reference

Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression

21 January 2018

1 reference

Early post-treatment pseudo-progression amongst glioblastoma multiforme patients treated with radiotherapy and temozolomide: a retrospective analysis

21 January 2018

1 reference

Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53.

21 January 2018

1 reference

Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status.

21 January 2018

1 reference

Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients.

21 January 2018

1 reference

Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma

21 January 2018

1 reference

Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide

21 January 2018

1 reference

Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.

21 January 2018

1 reference

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients

21 January 2018

1 reference

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

Diffusion-weighted MR imaging of rim-enhancing brain masses: is markedly decreased water diffusion specific for brain abscess?

21 January 2018

1 reference

Distinguishing recurrent primary brain tumor from radiation injury: a preliminary study using a susceptibility-weighted MR imaging-guided apparent diffusion coefficient analysis strategy.

21 January 2018

1 reference

Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study

21 January 2018

1 reference

Support vector machine multiparametric MRI identification of pseudoprogression from tumor recurrence in patients with resected glioblastoma

21 January 2018

1 reference

Differentiating treatment-induced necrosis from recurrent/progressive brain tumor using nonmodel-based semiquantitative indices derived from dynamic contrast-enhanced T1-weighted MR perfusion.

21 January 2018

1 reference

21 January 2018

1 reference

Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI.

21 January 2018

1 reference

Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival

21 January 2018

1 reference

Improved perfusion MR imaging assessment of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model with ferumoxytol

21 January 2018

1 reference

The parametric response map is an imaging biomarker for early cancer treatment outcome

21 January 2018

1 reference

Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis

21 January 2018

1 reference

Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy

21 January 2018

1 reference

Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury.

21 January 2018

1 reference

Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging.

21 January 2018

1 reference

Distinction between glioma progression and post-radiation change by combined physiologic MR imaging

21 January 2018

1 reference

F-18 FDG PET-CT in patients with recurrent glioma: comparison with contrast enhanced MRI.

21 January 2018

1 reference

Clinical applications of PET in brain tumors

21 January 2018

1 reference

Discriminant analysis of ¹⁸F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma

21 January 2018

1 reference

Differentiation of recurrent astrocytoma from radiation necrosis: a pilot study with 13N-NH3 PET.

21 January 2018

1 reference

Non selective transport of [11C-methyl]-L-and D-methionine into a malignant glioma.

21 January 2018

1 reference

Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery--in malignant glioma

21 January 2018

1 reference

Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy

21 January 2018

1 reference

Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors.

21 January 2018

1 reference

Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas

21 January 2018

1 reference

The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment

21 January 2018

1 reference

18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience

21 January 2018

1 reference

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

21 January 2018

1 reference

Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment.

21 January 2018

1 reference

Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series

21 January 2018

1 reference

Cerebral radionecrosis: Incidence and risk in relation to dose, time, fractionation and volume

21 January 2018

1 reference

Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme

21 January 2018

1 reference

Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERN.13.7

1 reference

28 August 2017

1 reference

PubMed ID

23545054